Published in Genet Vaccines Ther on June 08, 2009
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients | NCT00563173
HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells. Viruses (2015) 0.96
Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol (2010) 0.89
DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice. BMC Infect Dis (2013) 0.86
The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Clin Vaccine Immunol (2010) 0.84
Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization. Hum Vaccin Immunother (2013) 0.82
Hepatitis C virus and vaccine development. Int J Mol Cell Med (2014) 0.80
The evaluation of hepatitis C virus core antigen in immunized BALB/c mice. Hepat Mon (2012) 0.78
Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS One (2012) 0.78
Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease. Neurol Sci (2013) 0.76
Protection via a ROM4 DNA vaccine and peptide against Toxoplasma gondii in BALB/c mice. BMC Infect Dis (2017) 0.75
Immunization with Brugia malayi Myosin as Heterologous DNA Prime Protein Boost Induces Protective Immunity against B. malayi Infection in Mastomys coucha. PLoS One (2016) 0.75
Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA. J Immunol Res (2015) 0.75
Heterologous Prime-Boost Vaccination Enhances TsPmy's Protective Immunity against Trichinella spiralis Infection in a Murine Model. Front Microbiol (2017) 0.75
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature (1984) 7.54
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci U S A (1993) 3.68
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol (1997) 2.98
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
Alternative mechanisms of initiating translation of mammalian mRNAs. Biochem Soc Trans (2005) 2.17
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today (2000) 2.03
Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol (1996) 2.02
Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat (2000) 1.98
Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol (1998) 1.92
Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res (2001) 1.91
The native form and maturation process of hepatitis C virus core protein. J Virol (1998) 1.91
Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol (2006) 1.87
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol (2001) 1.84
p26 protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts. Virology (1992) 1.84
Hepatitis C virus biology. Cell Death Differ (2003) 1.83
Role of ATP in binding and migration of 40S ribosomal subunits. Cell (1980) 1.82
Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun (2003) 1.81
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol (2001) 1.81
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 1.69
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J Virol (1999) 1.63
Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res (1995) 1.58
Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology (2008) 1.57
Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted. J Gen Virol (1995) 1.52
Suppression of apoptotic cell death by hepatitis C virus core protein. Virology (1996) 1.46
Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 1.40
Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol (1997) 1.30
The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology (2000) 1.23
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 1.22
Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitis C virus. J Virol (2000) 1.22
Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci (2005) 1.21
The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine (2008) 1.17
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol (2005) 1.17
Hepatitis C virus genotypes and quasispecies. Am J Med (1999) 1.15
The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med (Berl) (1996) 1.14
Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther (2004) 1.13
Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. Hepatology (2002) 1.12
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine (2006) 1.11
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol (1999) 1.10
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol Cells (1997) 1.09
Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology (2002) 1.08
Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine (2000) 1.08
Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol (1995) 1.08
Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol (2007) 1.07
Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin (2008) 1.06
DNA vaccines: improving expression of antigens. Genet Vaccines Ther (2003) 1.04
Specific in vitro association between the hepatitis C viral genome and core protein. J Med Virol (1999) 1.04
Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine (2005) 1.04
DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther (2008) 1.03
Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells. J Gen Virol (2003) 1.00
Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology (2001) 0.99
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine (2007) 0.99
Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J Virol (2003) 0.98
Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. J Hepatol (1994) 0.98
Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis (2008) 0.96
Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane. Cell Microbiol (2006) 0.96
Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol (1999) 0.95
Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine (2007) 0.93
Cloning and characterization of a complete open reading frame of the hepatitis C virus genome in only two cDNA fragments. J Gen Virol (1997) 0.92
Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat (2007) 0.92
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine (2007) 0.91
Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology (1996) 0.91
Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect Immun (2000) 0.90
Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine (1999) 0.88
Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr Pharm Biotechnol (2003) 0.88
Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat (2002) 0.88
Hepatitis C virus core protein: its coordinate roles with PA28gamma in metabolic abnormality and carcinogenicity in the liver. Int J Biochem Cell Biol (2008) 0.88
Natural history and disease manifestations of hepatitis C infection. Curr Top Microbiol Immunol (2000) 0.88
Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine (2006) 0.88
Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology (2006) 0.87
Syringe exchanges: a public health response to problem drug use. Ir Med J (2000) 0.86
Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis (1996) 0.86
Hepatitis C virus: structure, protein products and processing of the polyprotein precursor. Curr Stud Hematol Blood Transfus (1994) 0.86
Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine (2008) 0.85
Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol (2006) 0.84
Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity. Protein Expr Purif (2006) 0.84
DNA prime protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge. J Gen Virol (2008) 0.83
Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med (2009) 0.82
A truncated variant of the hepatitis C virus core induces a slow but potent immune response in mice following DNA immunization. Vaccine (2000) 0.82
Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol (2007) 0.81
Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells. Vaccine (2004) 0.81
Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. J Med Virol (1999) 0.81
Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine (2005) 0.81
[Genome analysis of hepatitis C virus strain 274933RU isolated in Russian Federation]. Vopr Virusol (2002) 0.80
T helper and B cell escape mutations within the HBc gene in patients with asymptomatic HBV infection: a study from the South-Eastern region of Iran. Clin Lab (2012) 1.52
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog (2009) 1.10
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology (2013) 1.02
The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol (2009) 1.01
EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci U S A (2008) 1.01
Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope. Arthritis Rheum (2006) 1.01
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther (2005) 1.01
Immune dysregulation by the rheumatoid arthritis shared epitope. J Immunol (2010) 1.00
The rheumatoid arthritis shared epitope increases cellular susceptibility to oxidative stress by antagonizing an adenosine-mediated anti-oxidative pathway. Arthritis Res Ther (2007) 0.99
Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol (2009) 0.98
N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol (2010) 0.97
CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J Clin Virol (2009) 0.97
An outbreak of HBV and HCV infection in a paediatric oncology ward: epidemiological investigations and prevention of further spread. J Med Virol (2003) 0.96
Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol (2003) 0.95
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol (2005) 0.94
Induction of metabolic acidosis with ammonium chloride (NH4Cl) in mice and rats--species differences and technical considerations. Cell Physiol Biochem (2011) 0.92
Identification of the rheumatoid arthritis shared epitope binding site on calreticulin. PLoS One (2010) 0.92
Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine (2010) 0.92
A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice. PLoS One (2013) 0.92
Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol (2010) 0.89
Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine (2006) 0.89
Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology (2002) 0.87
Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches. Mol Biotechnol (2012) 0.85
An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology (2004) 0.85
Acute parathyroid hormone differentially regulates renal brush border membrane phosphate cotransporters. Pflugers Arch (2010) 0.85
Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol (2006) 0.84
Monoclonal antibodies providing topological information on the duck hepatitis B virus core protein and avihepadnaviral nucleocapsid structure. J Virol (2007) 0.84
A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther (2012) 0.84
Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity. Protein Expr Purif (2006) 0.84
Fibronectin-binding nanoparticles for intracellular targeting addressed by B. burgdorferi BBK32 protein fragments. Nanomedicine (2012) 0.81
Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. Protein Expr Purif (2010) 0.81
High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers. Vaccine (2008) 0.81
Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization. Vaccine (2010) 0.80
Vaccination against drug resistance in HIV infection. Expert Rev Vaccines (2008) 0.80
Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging. Mol Imaging (2012) 0.80
Assembly of bacteriophage Qbeta virus-like particles in yeast Saccharomyces cerevisiae and Pichia pastoris. J Biotechnol (2006) 0.80
Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. PLoS One (2013) 0.80
Mosaic particles formed by wild-type hepatitis B virus core protein and its deletion variants consist of both homo- and heterodimers. FEBS Lett (2003) 0.79
HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. Vaccine (2005) 0.79
Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface. J Gen Virol (2004) 0.79
Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection. Virol J (2012) 0.78
Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol J (2008) 0.78
Fine-mapping of the B-cell epitope domain at the N-terminus of the preS2 region of the hepatitis B surface antigen. J Immunol Methods (2002) 0.78
Proteasomal degradation of core protein variants from chronic hepatitis B patients. J Med Virol (2007) 0.77
Hamster polyomavirus-derived virus-like particles are able to transfer in vitro encapsidated plasmid DNA to mammalian cells. Virus Genes (2006) 0.77
Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice. Viral Immunol (2002) 0.76
Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein. Mol Biotechnol (2014) 0.76
Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein. Clin Vaccine Immunol (2013) 0.76
Autoimmunogenicity of the helix-loop-helix DNA-binding domain. Mol Immunol (2009) 0.76
High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model. BMC Cancer (2014) 0.75
Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants. Virol J (2013) 0.75
Hepatitis B and C virus variants in long-term immunosuppressed renal transplant patients in Latvia. Intervirology (2005) 0.75
Stop codon insertion restores the particle formation ability of hepatitis B virus core-hantavirus nucleocapsid protein fusions. Intervirology (2002) 0.75
Structural changes in lymphocytes membrane of Chernobyl clean-up workers from Latvia. J Fluoresc (2007) 0.75
Fluorescent probe ABM and estimation of immune state in patients with different pathologies (review article). J Fluoresc (2009) 0.75
Translation of hepatitis B virus (HBV) surface proteins from the HBV pregenome and precore RNAs in Semliki Forest virus-driven expression. J Gen Virol (2004) 0.75